Crinetics scores $40 mln Series A
San Diego, California-based Crinetics Pharmaceuticals, which is focused on treating specialty endocrine disorders, has closed $40 million in Series A financing. Versant Ventures, 5AM Ventures and Vivo Capital led the round. In addition to the funding, Dr. Wendell Wierenga has been named chairman of Crinetics’ board of directors. Also, Crinetics has appointed Dr. Mason Freeman of 5AM Ventures, Dr. Steve Kaldor of Versant Ventures and Dr. Mahendra Shah of Vivo Capital to its board of directors.
2 November 2015•3 mins read
